

Oral Proteins and Oral Peptides Market (4th Edition) by Target Disease Indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), Type of Molecule (protein and peptide), Technology Platforms, Biological Target (GC-C, insulin receptor, oxalate and others), Mechanism of Action (receptor stimulation, substrate degradation and others), Key Players, and Key Geographical Regions (North America, Europe, Asia-Pacific and RoW), 2022-2032

<https://marketpublishers.com/r/O55ACA980D32EN.html>

Date: February 2022

Pages: 481

Price: US\$ 4,799.00 (Single User License)

ID: O55ACA980D32EN

Abstracts

The oral protein and oral peptide market is expected to reach USD 1.4 billion in 2022 anticipated to grow at a CAGR of 20% during the forecast period 2022-2032

Since the introduction of the initial protein-based therapy, recombinant human insulin, in 1982, there has been a significant surge in research and development dedicated to such medicinal products. Initially administered subcutaneously, technological advancements in delivery formulations have catalyzed the ascent of orally administered therapeutic interventions. This transition has piqued the interest of stakeholders, leading to a focused effort on crafting proteins and peptides suitable for oral ingestion. Notably, within the last decade, three peptide-based therapies—Mycapssa® (2020), Trulance® (2017), and Linzess® (2012)—have secured FDA approval, making successful market entries across various global regions. The escalating popularity of this emerging therapeutic category has spurred the reformulation and advancement of oral protein and

peptide-based treatments for numerous disease indications spanning metabolic, gastrointestinal, and autoimmune disorders.

The oral delivery of peptide pills presents distinct advantages, especially for pediatric and geriatric patients, owing to its non-invasive nature. Furthermore, its straightforwardness has demonstrated an ability to improve treatment adherence while reducing the likelihood of non-compliance. Protein and peptide-based therapeutics have profoundly influenced the pharmaceutical landscape due to their diverse applications and targeted therapeutic properties. Nonetheless, formulating these drugs for oral intake has encountered challenges, including low bioavailability and susceptibility to degradation within the gastrointestinal tract. To confront these obstacles, companies operating in the oral protein and peptide market have undertaken extensive research, focusing on innovating novel biological targets to fortify their research pipelines. This particular industry segment has garnered significant attention from private and public sector investors who have provided considerable financial support to drive these initiatives. Notably, major pharmaceutical companies have increasingly engaged in this sector, resulting in substantial partnership activities.

Given the ongoing research and development endeavors alongside the favorable reception of already commercialized drugs, the market for oral protein and peptide therapies is poised for substantial growth in the forecasted period.

Report Coverage

Summary of key research insights on the current state and future evolution of the oral protein/peptide therapeutics market.

Introduction comparing small molecules and large molecules (biologics), discusses proteins/peptides as therapeutic agents, explores drug delivery routes, and examines challenges and advantages of oral administration.

Details over 125 programs for oral protein/peptide therapeutics, analyzing their phases, target areas, mechanisms, and developer information.

A competitive analysis of therapy developers based on parameters like pipeline strength and development phase.

A competitive analysis of therapy developers based on parameters like pipeline strength and development phase.

An insight derived from the study, featuring schematic representations of the product pipeline and developer companies.

Identification of key opinion leaders (KOLs) in the field, assessing their experience and contributions.

Prime target indications for oral proteins/peptides, detailing disease epidemiology, diagnostic tests, treatment options, and likely side effects.

Detailed profiles of marketed or late-stage oral protein/peptide drugs, including development history, mechanisms, clinical trials, and developer information.

Technology platforms for oral protein/peptide development and the companies involved based on establishment year, size, and headquarters.

Product competitiveness and supplier power of oral drug delivery technology platforms based on several parameters.

Profiles of key technologies used in oral protein/peptide therapeutics, including mechanisms, pipeline molecules, advantages, and partnerships.

Detailed investments received by companies in this field, analyzing funding instances based on parameters like amount invested, focus area, and geographical analysis.

Detailed collaborations established since 2017, categorizing them by type, focus area, partner type, and regional distribution.

An in-depth analysis of patents related to oral protein/peptides filed or granted since 2017, including geographical distribution, legal status, and leading players.

Big pharma players engaged in oral protein/peptide therapeutics based on pipeline candidates, partnerships, and publications.

A detailed market forecast analysis, projecting the growth of oral protein/peptide therapeutics till 2032 based on various segmentation parameters.

Key Market Companies

Anthera Pharmaceuticals

Carmot Therapeutics

IGY Life Sciences and Technology

Constant Therapeutics

Contents

1. PREFACE

- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

- 2.1. Chapter Overview

3. INTRODUCTION

- 3.1. Chapter Overview
- 3.2. Comparison of Biologics and Small Molecules
- 3.3. Introduction to Proteins
 - 3.3.1. Protein Structure
 - 3.3.2. Classification of Proteins
- 3.4. Introduction to Peptides
 - 3.4.1. Peptide Structure
 - 3.4.2. Classification of Peptides
 - 3.4.2.1. Synthetic Peptides
 - 3.4.2.2. Recombinant Peptides
- 3.5. Routes of Administration for Proteins / Peptides
 - 3.5.1. Parenteral Administration
 - 3.5.1.1. Intramuscular Route
 - 3.5.1.2. Intravenous Route
 - 3.5.1.3. Subcutaneous Route
 - 3.5.2. Non-Parenteral Administration
 - 3.5.2.1. Buccal / Sublingual Route
 - 3.5.2.2. Intranasal Route
 - 3.5.2.3. Oral Route
 - 3.5.2.4. Ocular Route
 - 3.5.2.5. Pulmonary Route / Inhalation
 - 3.5.2.6. Rectal Route
 - 3.5.2.7. Transdermal Route
 - 3.5.3. Comparison of Different Routes of Drug Administration

- 3.6. Oral Delivery of Proteins / Peptides
 - 3.6.1. Key Advantages of Oral Administration
 - 3.6.2. Key Challenges Associated with Oral Administration
- 3.7. Approaches Used for Structural and Bioavailability Enhancement
 - 3.7.1. Absorption Enhancers
 - 3.7.2. Chemical Modification
 - 3.7.2.1 Pro Drug Approach
 - 3.7.3. Enzyme Inhibitors
 - 3.7.4. Muco-Adhesive Polymeric Systems
 - 3.7.5. Nanoparticulate Delivery Systems
 - 3.7.5.1. Liposomes
 - 3.7.5.2. Nanoparticles / Microparticles
 - 3.7.6. PEGylation
- 3.8. Concluding Remarks

4. MARKET OVERVIEW

- 4.1. Chapter Overview
- 4.2. Oral Proteins / Peptide Therapeutics: Market Landscape
 - 4.2.1. Analysis by Type of Molecule
 - 4.2.2. Analysis by Phase of Development
 - 4.2.3. Analysis by Target Therapeutic Area
 - 4.2.4. Analysis by Biological Target
 - 4.2.5. Analysis by Mechanism of Action
 - 4.2.6. Analysis by Phase of Development and Mechanism of Action
 - 4.2.7. Analysis by Number of Amino Acids
 - 4.2.8. Key Drug Development Platforms: Analysis by Number of Products
- 4.3. Oral Proteins / Peptide Therapeutics: Developer Landscape
 - 4.3.1. Analysis by Year of Establishment
 - 4.3.2. Analysis by Company Size
 - 4.3.3. Analysis by Location of Headquarters
 - 4.3.4. Analysis by Company Size and Location of Headquarters
 - 4.3.5. Most Active Players: Analysis by Number of Pipeline Candidates

5. COMPANY COMPETITIVENESS ANALYSIS

- 5.1. Chapter Overview
- 5.2. Key Assumptions and Parameters
- 5.3. Oral Protein / Peptide Therapy Developers: Competitiveness Analysis

6. KEY INSIGHTS

- 6.1. Chapter Overview
- 6.2. Oral Proteins / Peptides Pipeline: Grid Analysis
- 6.3. Oral Proteins / Peptides Pipeline: Developer Landscape
- 6.4. Oral Proteins / Peptides Pipeline: Regional Landscape (Industry Players)

7. KOL ANALYSIS

- 7.1. Chapter Overview
- 7.2. Oral Protein / Peptide Therapeutics: List of Key Opinion Leaders
 - 7.2.1. Analysis by Type of Current Organization
 - 7.2.2. Analysis by Geography
 - 7.2.2.1. Analysis by Region (Continent-wise)
 - 7.2.2.2. Analysis by Region (Country-wise)
 - 7.2.3. Analysis by Number of Investigators and Current Organization
 - 7.2.4. Analysis by Qualification of KOL
 - 7.2.5. Comparison of KOL Activeness v/s Strength (Scatter Plot)
 - 7.2.6. Comparison of Roots Analysis Score v/s Third Party Score
 - 7.2.7. Prominent Players: Comparison of Roots Analysis Score v/s Third Party Score
 - 7.2.8. Most Active Key Opinion Leaders: Comparison of Professional Network v/s Academic Strength

8. KEY THERAPEUTIC AREAS

- 8.1. Chapter Overview
- 8.2. Metabolic Disorders
 - 8.2.1. Diabetes
 - 8.2.1.1. Disease Description
 - 8.2.1.2. Associated Health Risks / Complications
 - 8.2.1.3. Epidemiology
 - 8.2.1.4. Disease Diagnosis
 - 8.2.1.5. Current Treatment Options
 - 8.2.1.5.1. Insulin Therapies
 - 8.2.1.5.2. Non-Insulin Therapies
 - 8.2.1.6. Side Effects of Current Treatment Options
 - 8.2.1.7. Oral Proteins / Peptides for Diabetes
 - 8.2.2. Obesity

- 8.2.2.1. Disease Description
- 8.2.2.2. Epidemiology
- 8.2.2.3. Current Treatment Options
- 8.2.2.4. Side Effects of Current Treatment Options
- 8.2.2.5. Oral Proteins / Peptides for Obesity
- 8.2.3. Non-alcoholic Steatohepatitis (NASH)
 - 8.2.3.1. Disease Description
 - 8.2.3.2. Epidemiology
 - 8.2.3.3. Current Treatment Options
 - 8.2.3.4. Oral Proteins / Peptides for NASH
- 8.3. Digestive and Gastrointestinal Disorders
 - 8.3.1. Ulcerative Colitis
 - 8.3.1.1. Disease Description
 - 8.3.1.2. Epidemiology
 - 8.3.1.3. Current Treatment Options
 - 8.3.1.4. Side Effects of Current Treatment Options
 - 8.3.1.5. Oral Proteins / Peptides for Ulcerative Colitis
 - 8.3.2. Crohn's Disease
 - 8.3.2.1. Disease Description
 - 8.3.2.2. Epidemiology
 - 8.3.2.3. Current Treatment Options
 - 8.3.2.4. Side Effects of Current Treatment Options
 - 8.3.2.5. Oral Proteins / Peptides for Crohn's Disease
- 8.4. Infectious Diseases
 - 8.4.1. C. difficile Infections (CDIs)
 - 8.4.1.1. Disease Description
 - 8.4.1.2. Epidemiology
 - 8.4.1.3. Disease Diagnosis
 - 8.4.1.4. Current Treatment Options
 - 8.4.1.5. Side Effects of Current Treatment Options
 - 8.4.1.6. Oral Proteins / Peptides for CDIs
- 8.5. Autoimmune Disorders
 - 8.5.1. Celiac Disease
 - 8.5.1.1. Disease Description
 - 8.5.1.2. Epidemiology
 - 8.5.1.3. Disease Diagnosis
 - 8.5.1.4. Current Treatment Options
 - 8.5.1.5. Oral Proteins / Peptides for Celiac Disease
- 8.6. Hormonal Disorders

- 8.6.1. Acromegaly
 - 8.6.1.1. Disease Description
 - 8.6.1.2. Epidemiology
 - 8.6.1.3. Disease Diagnosis
 - 8.6.1.4. Current Treatment Options
 - 8.6.1.5. Side Effects of Current Treatment Options
 - 8.6.1.6. Oral Proteins / Peptides for Acromegaly

8.7. Bone Disorders

- 8.7.1. Osteoporosis
 - 8.7.1.1. Disease Description
 - 8.7.1.2. Epidemiology
 - 8.7.1.3. Disease Diagnosis
 - 8.7.1.4. Current Treatment Options
 - 8.7.1.5. Side Effects of Current Treatment Options
 - 8.7.1.6. Oral Proteins / Peptides for Osteoporosis

9. MARKETED AND LATE-STAGE DRUG PROFILES

9.1. Chapter Overview

9.2. Linzess® / Constella® / Linaclotide (Ironwood Pharmaceuticals)

- 9.2.1. Drug Overview
- 9.2.2. History of Development
- 9.2.3. Mechanism of Action
- 9.2.4. Dosage Form, Treatment Regimen and Price
- 9.2.5. Manufacturing Information
- 9.2.6. Current Status of Development
- 9.2.7. Clinical Studies
- 9.2.8. Key Clinical Trial Results
- 9.2.9. Historical Sales
- 9.2.10. Developer Overview

9.3. Trulance® / Plecanatide (Synergy Pharmaceuticals)

- 9.3.1. Drug Overview
- 9.3.2. History of Development
- 9.3.3. Mechanism of Action
- 9.3.4. Dosage Form, Treatment Regimen and Price
- 9.3.5. Manufacturing Information
- 9.3.6. Current Status of Development
- 9.3.7. Clinical Studies
- 9.3.8. Key Clinical Trial Results

- 9.3.9. Historical Sales
- 9.3.10. Developer Overview
- 9.4. TBRIA™ / Oral Calcitonin (Tarsa Therapeutics / Enteris BioPharma)
 - 9.4.1. Drug Overview
 - 9.4.2. History of Development
 - 9.4.3. Mechanism of Action
 - 9.4.4. Manufacturing Information
 - 9.4.5. Current Status of Development
 - 9.4.6. Clinical Studies
 - 9.4.7. Key Clinical Trial Results
 - 9.4.8. Developer Overview
- 9.5. Mycapssa® / (Chiasma Pharma)
 - 9.5.1. Drug Overview
 - 9.5.2. History of Development
 - 9.5.3. Mechanism of Action
 - 9.5.4. Manufacturing Information
 - 9.5.5. Current Status of Development
 - 9.5.6. Clinical Studies
 - 9.5.7. Key Clinical Trial Results
 - 9.5.8. Developer Overview
- 9.6. ALLN-177 (Allena Pharmaceuticals)
- 9.7. INN-202 (9 Meters Biopharma)
- 9.8. ORMD-0801 (Oramed Pharmaceuticals)
- 9.9. IN-105 (Biocon)
- 9.10. Oral HDV Insulin (Diasome Pharmaceuticals)

10. CASE STUDIES: MINIRIN®, SANDIMMUNE® AND SOLLPURA®

- 10.1. Chapter Overview
- 10.2. Minirin® / DDAVP (Ferring Pharmaceuticals)
 - 10.2.1. Drug Overview
 - 10.2.2. History of Development
 - 10.2.3. Chemical Structure and Mechanism of Action
 - 10.2.4. Dosage Form, Treatment Regimen and Price
 - 10.2.5. Patent Portfolio
 - 10.2.6. Competitive Landscape
- 10.3. Sandimmune® / Neoral® (Novartis)
 - 10.3.1. Drug Overview
 - 10.3.2. History of Development

- 10.3.3. Mechanism of Action
- 10.3.4. Dosage Form, Treatment Regimen and Price
- 10.3.5. Patent Portfolio
- 10.3.6. Competitive Landscape
- 10.4. Sollpura® / Liprotamase (Anthera Pharmaceuticals)
 - 10.4.1. Drug Overview
 - 10.4.2. History of Development
 - 10.4.3. Chemical Structure and Mechanism of Action
 - 10.4.4. Current Status of Development
 - 10.4.5. Clinical Studies
 - 10.4.6. Competitive Landscape

11. ORAL PROTEIN / PEPTIDE DEVELOPMENT TECHNOLOGIES: MARKET LANDSCAPE

- 11.1. Chapter Overview
- 11.2. Oral Protein / Peptide Development Technologies: Market Landscape
 - 11.2.1. Analysis by Type of Technology
 - 11.2.2. Analysis by Compatible API Types
 - 11.2.3. Analysis by Target Therapeutic Area
 - 11.2.4. Analysis by Dosage Form
 - 11.2.5. Analysis by Status of Development of Products
- 11.3. Oral Protein / Peptide Development Technologies: Developer Landscape
 - 11.3.1. Analysis by Year of Establishment
 - 11.3.2. Analysis by Company Size
 - 11.3.3. Analysis by Location of Headquarters
 - 11.3.4. Analysis by Company Size and Location of Headquarters

12. PRODUCT COMPETITIVENESS ANALYSIS

- 12.1. Chapter Overview
- 12.2. Scope and Methodology
- 12.3. Product Competitiveness Analysis: Key Technologies

13. ORAL DRUG DELIVERY TECHNOLOGY PLATFORMS

- 13.1. Chapter Overview
- 13.2. Oral Drug Delivery: List of Technology Platforms
- 13.3. Technology Profiles

- 13.3.1. Axxess™ Oral Drug Delivery Technology (Proxima Concepts)
 - 13.3.1.1. Developer Overview
 - 13.3.1.2. Technology Overview
 - 13.3.1.3. Drug Delivery Mechanism
 - 13.3.1.4. Key Advantages
 - 13.3.1.5. Oral Proteins / Peptides Pipeline
 - 13.3.1.6. Collaborations
- 13.3.2. Eligen™ Technology (Emisphere Technologies)
 - 13.3.2.1. Developer Overview
 - 13.3.2.2. Technology Overview
 - 13.3.2.3. Drug Delivery Mechanism
 - 13.3.2.4. Key Advantages
 - 13.3.2.5. Oral Proteins / Peptides Pipeline
 - 13.3.2.6. Collaborations
- 13.3.3. Entera Technology (Entera Bio)
 - 13.3.3.1. Developer Overview
 - 13.3.3.2. Technology Overview
 - 13.3.3.3. Drug Delivery Mechanism
 - 13.3.3.4. Key Advantages
 - 13.3.3.5. Oral Proteins / Peptides Pipeline
- 13.3.4. NTRA Oral Delivery Technology (Nutrinia)
 - 13.3.4.1. Developer Overview
 - 13.3.4.2. Technology Overview
 - 13.3.4.3. Drug Delivery Mechanism
 - 13.3.4.4. Key Advantages
 - 13.3.4.5. Oral Proteins / Peptides Pipeline
- 13.3.5. Peptelligence® Technology (Enteris BioPharma)
 - 13.3.5.1. Developer Overview
 - 13.3.5.2. Technology Overview
 - 13.3.5.3. Drug Delivery Mechanism
 - 13.3.5.4. Key Advantages
 - 13.3.5.5. Oral Proteins / Peptides Pipeline
 - 13.3.5.6. Collaborations
- 13.3.6. Protein Oral Delivery (POD™) Technology (Oramed Pharmaceuticals)
 - 13.3.6.1. Developer Overview
 - 13.3.6.2. Technology Overview
 - 13.3.6.3. Drug Delivery Mechanism
 - 13.3.6.4. Key Advantages
 - 13.3.6.5. Oral Proteins / Peptides Pipeline

13.3.7. Transient Permeability Enhancer (TPE®) Technology (Chiasma Pharma)

13.3.7.1. Developer Overview

13.3.7.2. Technology Overview

13.3.7.3. Drug Delivery Mechanism

13.3.7.4. Key Advantages

13.3.7.5. Oral Proteins / Peptides Pipeline

13.3.8. Uroguanylin Analogue Technology (Synergy Pharmaceuticals)

13.3.8.1. Developer Overview

13.3.8.2. Technology Overview

13.3.8.3. Drug Delivery Mechanism

13.3.8.4. Key Advantages

13.3.8.5. Oral Proteins / Peptides Pipeline

14. FUNDING AND INVESTMENT ANALYSIS

14.1. Chapter Overview

14.2. Types of Funding

14.3. Oral Proteins / Peptides: Funding and Investment Analysis

14.3.1. Analysis by Cumulative Number of Funding Instances

14.3.2. Analysis by Cumulative Amount Invested

14.3.3. Analysis by Type of Funding

14.3.4. Analysis by Year, Type of Funding and Amount Invested

14.3.5. Analysis by Focus Area

14.3.6. Analysis by Area of Application

14.3.7. Analysis by Target Therapeutic Area

14.3.8. Analysis by Geography

14.3.9. Most Active Players: Analysis by Number of Instances

14.3.10. Most Active Players: Analysis by Amount Invested

14.4. Concluding Remarks

15. RECENT COLLABORATIONS

15.1. Chapter Overview

15.2. Partnership Models

15.3. Oral Proteins / Peptides: Partnerships and Collaborations

15.3.1. Analysis by Year of Partnership

15.3.2. Analysis by Type of Partnership

15.3.3. Analysis by Area of Application

15.3.4. Analysis by Type of Partner

- 15.3.5. Analysis by Focus Area
- 15.3.6. Analysis by Target Therapeutic Area
- 15.3.7. Most Active Players: Analysis by Number of Partnerships
- 15.3.8. Analysis by Geography
- 15.3.9. Intercontinental and Intracontinental Agreements

16. PUBLICATION ANALYSIS

- 16.1. Chapter Overview
- 16.2. Oral Proteins / Peptides: List of Publications
 - 16.2.1. Analysis by Year of Publication
 - 16.2.2. Analysis by Type of Molecule
 - 16.2.3. Analysis by Target Therapeutic Area
 - 16.2.4. Word Cloud of Study Titles
 - 16.2.5. Most Prominent Journals: Analysis by Number of Publications
 - 16.2.6. Most Prominent Authors: Analysis by Number of Publications

17. CLINICAL TRIAL ANALYSIS

- 17.1. Chapter Overview
- 17.2. Scope and Methodology
- 17.3. Oral Protein / Peptide Therapeutics: Clinical Trial Analysis
 - 17.3.1. Analysis by Trial Registration Year
 - 17.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
 - 17.3.3. Analysis by Trial Status
 - 17.3.4. Analysis by Trial Phase
 - 17.3.5. Analysis by Trial Registration Year and Trial Status
 - 17.3.6. Analysis by Enrolled Patient Population and Trial Phase
 - 17.3.7. Analysis by Type of Sponsor / Collaborator
 - 17.3.8. Analysis by Patient Segment
 - 17.3.9. Analysis by Target Therapeutic Area
 - 17.3.10. Analysis by Study Design
 - 17.3.11. Most Active Players: Analysis by Number of Registered Trials
 - 17.3.12. Analysis by Number of Trials and Geographical Location
 - 17.3.13. Analysis by Number of Trials, Trial Status and Geographical Location
 - 17.3.14. Analysis by Enrolled Patient Population and Trial Status

18. PATENT ANALYSIS

- 18.1. Chapter Overview
- 18.2. Scope and Methodology
- 18.3. Oral Protein / Peptide Therapeutics: Patent Analysis
 - 18.3.1. Analysis by Publication Year
 - 18.3.2. Analysis by Patent Jurisdiction
 - 18.3.3. Analysis by Legal Status
 - 18.3.4. Analysis by CPC Symbols
 - 18.3.5. Emerging Focus Areas
 - 18.3.6. Analysis by Type of Applicant
 - 18.3.7. Leading Players: Analysis by Number of Patents
 - 18.3.8. Key Inventors: Analysis by Number of Patents
- 18.4. Oral Protein / Peptide Therapeutics: Patent Benchmarking Analysis
 - 18.4.1. Analysis by Patent Characteristics
 - 18.4.2. Analysis by Geography
- 18.5. Oral Protein / Peptide Therapeutics: Patent Valuation Analysis

19. BIG PHARMA ANALYSIS

- 19.1. Chapter Overview
- 19.2. Key Assumptions and Methodology
- 19.3. Oral Protein / Peptide Therapeutics: Big Pharma Initiatives
 - 19.3.1. Analysis by Target Therapeutic Area
 - 19.3.2. Analysis by Type of Initiative
 - 19.3.3. Big Pharma Players: Benchmarking Analysis

20. MARKET FORECAST AND OPPORTUNITY ANALYSIS

- 20.1. Chapter Overview
- 20.2. Scope and Limitations
- 20.3. Forecast Methodology
- 20.4. Global Oral Protein / Peptide Therapy Market, 2022-2032
 - 20.4.1. Oral Protein / Peptide Therapy Market: Distribution by Target Disease Indication
 - 20.4.2. Oral Protein / Peptide Therapy Market: Distribution by Type of Molecule
 - 20.4.3. Oral Protein / Peptide Therapy Market: Distribution by Technology Platform
 - 20.4.4. Oral Protein / Peptide Therapy Market: Distribution by Biological Target
 - 20.4.5. Oral Protein / Peptide Therapy Market: Distribution by Mechanism of Action
 - 20.4.6. Oral Protein / Peptide Therapy Market: Distribution by Key Players
 - 20.4.7. Oral Protein / Peptide Therapy Market: Distribution by Geography

- 20.5. Oral Proteins / Peptides Market: Product-wise Sales Forecasts
 - 20.5.1. Linzess® / Constella® / Linaclotide (Ironwood Pharmaceuticals)
 - 20.5.1.1. Target Patient Population
 - 20.5.1.2. Sales Forecast
 - 20.5.2. Trulance® / Plecanatide (Synergy Pharmaceuticals)
 - 20.5.2.1. Target Patient Population
 - 20.5.2.2. Sales Forecast
 - 20.5.3. Mycapssa® / Octreolin (Chiasma Pharma)
 - 20.5.3.1. Target Patient Population
 - 20.5.3.2. Sales Forecast
 - 20.5.4. ALLN-177 (Allena Pharmaceuticals)
 - 20.5.4.1. Target Patient Population
 - 20.5.4.2. Sales Forecast
 - 20.5.5. Larazotide INN-202 (Innovate Biopharmaceuticals)
 - 20.5.5.1. Target Patient Population
 - 20.5.5.2. Sales Forecast
 - 20.5.6. Oral HDV Insulin (Diasome Pharmaceuticals)
 - 20.5.6.1. Target Patient Population
 - 20.5.6.2. Sales Forecast
 - 20.5.7. ORMD-0801 (Oramed Pharmaceuticals)
 - 20.5.7.1. Target Patient Population
 - 20.5.7.2. Sales Forecast
 - 20.5.8. IN-105 / Insulin Tregopil (Biocon)
 - 20.5.8.1. Target Patient Population
 - 20.5.8.2. Sales Forecast

21. CASE STUDY: PROTEIN / PEPTIDE MANUFACTURING

- 21.1. Chapter Overview
- 21.2. Key Steps Involved in Protein / Peptide Manufacturing
- 21.3. Challenges Associated with Protein / Peptide Manufacturing
- 21.4. Current Scenario of Protein / Peptide Manufacturing
- 21.5. Growing Demand for Contract Manufacturing
 - 21.5.1. Selecting A Suitable CMO Partner
 - 21.5.2. Protein / Peptide CMOs: Market Landscape
 - 21.5.2.1. Analysis by Year of Establishment
 - 21.5.2.2. Analysis by Company Size
 - 21.5.2.3. Analysis by Location of Headquarters

22. KEY COMMERCIALIZATION / LIFECYCLE MANAGEMENT STRATEGIES

- 22.1. Successful Drug Launch Strategy: ROOTS Framework
- 22.2. Successful Drug Launch Strategy: Product Differentiation
- 22.3. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
- 22.4. Key Commercialization / Lifecycle Management Strategies Adopted by Companies Focused on Oral Protein / Peptide Therapeutics
 - 22.4.1. Strategies Adopted Before Therapy Approval
- 22.5. Strategies Adopted During / Post Therapy Approval
- 22.6. Analysis by Ease of Implementation, Value Addition and Current Adoption (Harvey Ball Framework)

23. SWOT ANALYSIS

- 23.1. Chapter Overview
- 23.2. Comparison of SWOT Factors

24. CONCLUSION

- 24.1 Chapter Overview

25. EXECUTIVE INSIGHTS

- 25.1. Chapter Overview
- 25.2. Anthera Pharmaceuticals
 - 25.2.1. Company Snapshot
 - 25.2.2. Interview Transcript: Dinesh Srinivasan, Director
- 25.3. Carmot Therapeutics
 - 25.3.1. Company Snapshot
 - 25.3.2. Interview Transcript: Stig K Hansen, CEO
- 25.4. IGY Life Sciences and Technology
 - 25.4.1. Company Snapshot
 - 25.4.2. Interview Transcript: Terry Dyck, President and CEO
- 25.5. Constant Therapeutics
 - 25.5.1. Company Snapshot
 - 25.5.2. Interview Transcript: Richard Franklin, CEO

26. APPENDIX 1: RECENT DEVELOPMENTS

27. APPENDIX 2: TABULATED DATA

28. APPENDIX 3: LIST OF COMPANIES

I would like to order

Product name: Oral Proteins and Oral Peptides Market (4th Edition) by Target Disease Indication (acromegaly, celiac disease, chronic idiopathic constipation, enteric hyperoxaluria, inflammatory bowel disease and type II diabetes), Type of Molecule (protein and peptide), Technology Platforms, Biological Target (GC-C, insulin receptor, oxalate and others), Mechanism of Action (receptor stimulation, substrate degradation and others), Key Players, and Key Geographical Regions (North America, Europe, Asia-Pacific and RoW), 2022-2032

Product link: <https://marketpublishers.com/r/O55ACA980D32EN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O55ACA980D32EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970